Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2009
Intravitreal bevacizumab for CNV-complicated tilted disk syndrome.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Milani Paolo, Pece Alfredo, Moretti Giuseppe, Lino Pruneri, Scialdone Antonio
Аннотация
BACKGROUND: Tilted disc syndrome is a congenital anomaly characterized by an inferonasal "tilting" of the optic disc. We report three patients affected by macular neovascularisation-complicated tilted disk syndrome treated by intravitreal bevacizumab.
METHODS: Three interventional case reports are hereby documented. Ophthalmic evaluations were registered, including monthly visual acuity examination, OCT and fluorescein angiography before and after consecutive intravitreal injection of 1.25 mg bevacizumab (0.05 ml, Avastin).
RESULTS: All patients, aged more than 65 years, experienced decreased visual acuity after an observation period of 6 (two patients) and 3 months (one patient). Angiographic leakage with neuroretinal rarefaction and RPE/choriocapillary complex elevation at OCT remained persistent in two patients and reduced in one.
CONCLUSIONS: No benefit in terms of visual acuity was noted after intravitreal bevacizumab treatments. Larger studies should be conducted to confirm our small series observation.
METHODS: Three interventional case reports are hereby documented. Ophthalmic evaluations were registered, including monthly visual acuity examination, OCT and fluorescein angiography before and after consecutive intravitreal injection of 1.25 mg bevacizumab (0.05 ml, Avastin).
RESULTS: All patients, aged more than 65 years, experienced decreased visual acuity after an observation period of 6 (two patients) and 3 months (one patient). Angiographic leakage with neuroretinal rarefaction and RPE/choriocapillary complex elevation at OCT remained persistent in two patients and reduced in one.
CONCLUSIONS: No benefit in terms of visual acuity was noted after intravitreal bevacizumab treatments. Larger studies should be conducted to confirm our small series observation.
Предметные рубрики MeSH
AgedAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabChoroidal NeovascularizationEye AbnormalitiesFemaleFluorescein AngiographyHumansInjectionsMaleOptic DiskSyndromeTomography, Optical CoherenceTreatment OutcomeVascular Endothelial Growth Factor AVisual AcuityVitreous Body